Boehringer Ingelheim Venture Fund returned to reinvest in the regenerative therapy developer after backing its series A round two years ago.
US-based regenerative therapy developer AgomAb Therapeutics has completed a $74m series B round that included Boehringer Ingelheim Venture Fund, the corporate venturing arm of pharmaceutical firm Boehringer Ingelheim.
Hedge fund manager Redmile Group led the round, which also featured Cormorant Asset Management, Advent France Biotechnology, Andera Partners, Omnes Capital, Pontifax and V-Bio Ventures.
AgomAb is developing monoclonal antibody drugs intended to repair tissue and restore organ function by modulating regenerative cellular pathways, in order to treat diseases and disorders based…
